NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

Mitchell, Paul; Siva, Shankar; Kok, Peey Sei; O'Byrne, Ken; Yeung, Annie; Livingstone, Ann; Donoghoe, Mark; Yip, Sonia; Stockier, Martin R

File(s) not publicly available

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

journal contribution

posted on 2023-05-18, 06:05 authored by Paul Mitchell, Shankar Siva, Peey Sei Kok, Ken O'Byrne, Annie Yeung, Ann Livingstone, Mark Donoghoe, Sonia Yip, Martin R Stockier

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

History

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume

15

Pagination

1-1

Location

IL, Chicago

Publisher DOI

https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS9097

ISSN

0732-183X

eISSN

1527-7755

Language

English

Author URL

https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411932202155&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Publication classification

E3 Extract of paper

Publisher

AMER SOC CLINICAL ONCOLOGY

Usage metrics

Keywords

Life Sciences & Biomedicine Oncology Science & Technology Oncology and Carcinogenesis not elsewhere classified Clinical Sciences not elsewhere classified

File(s) not publicly available

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

History

Journal

Volume

Pagination

Location

Publisher DOI

ISSN

eISSN

Language

Author URL

Publication classification

Publisher

Usage metrics

Categories

Keywords

Licence

Exports